HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E.l.f. Beauty Targeting Up To 39% Growth In Fiscal 2024 After Q1 Sales Soar 76%

Executive Summary

E.l.f. is one of only five public consumer companies out of 274 that has grown for 18 straight quarters and averaged at least 20% sales growth per quarter, chairman and CEO Tarang Amin noted during the Oakland, CA-based firm’s 1 August call to discuss Q1 results.

You may also be interested in...



'Close To A Perfect Quarter': E.l.f.'s Retail Partners Adding Shelf Space For Brand As Growth Streak Continues

E.l.f. Beauty, Inc. says retailer CVS will more than double its shelf space in US stores in spring 2024, while Walmart will provide more space for the e.l.f. brand this summer. In a 6 February earnings report, the Oakland, Calif.-based firm reported its sales jumped 86% in the fiscal third quarter to $270.9m.

E.l.f. Eyes Becoming Top Three Cosmetic Brand In Canada, UK As Non-US Sales Soar 157%

E.l.f. Beauty ranks fourth among cosmetic brands in Canada with 7% market share and number six in the UK with 5% share as its non-US sales soar 157% in its latest quarter.

E.l.f. Steps Up Skin-Care Game With $355M Naturium Acquisition

E.l.f. Beauty, Inc. will purchase LA-based Naturium skin care, a “thoughtfully formulated,” “high-performance” skin-care brand out of Los Angeles, for $355m from brand incubator The Center. Expected to close in September, the transaction will double e.l.f.’s skin-care business as a percentage of overall sales.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel